Literature DB >> 34820770

Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer.

Sanjay Divakaran1,2, Jesse P Caron2, Wunan Zhou1, Jon Hainer1, Courtney F Bibbo1, Hicham Skali1,2, Viviany R Taqueti1, Sharmila Dorbala1, Ron Blankstein1,2, John D Groarke2, Anju Nohria2, Marcelo F Di Carli3,4.   

Abstract

BACKGROUND: Impaired MFR in the absence of flow-limiting CAD is associated with adverse events. Cardiovascular disease is an important cause of morbidity and mortality in patients with breast cancer. We sought to test the utility of MFR to predict outcomes in a cohort of patients with breast cancer.
METHODS: We retrospectively studied consecutive patients with breast cancer or breast cancer survivors who underwent cardiac stress PET imaging from 2006 to 2017 at Brigham and Women's Hospital. Patients with a history of clinically overt CAD, LVEF < 45%, or abnormal myocardial perfusion were excluded. Subjects were followed from time of PET to the occurrence of a first major adverse cardiovascular event (MACE) and all-cause death.
RESULTS: The final cohort included 87 patients (median age 69.0 years, 98.9% female, mean MFR 2.05). Over a median follow-up of 7.6 years after PET, the lowest MFR tertile was associated with higher cumulative incidence of MACE (adjusted subdistribution hazard ratio 4.91; 95% CI 1.68-14.38; p = 0.004) when compared with the highest MFR tertile.
CONCLUSIONS: In patients with breast cancer, coronary vasomotor dysfunction was associated with incident cardiovascular events. MFR may have potential as a risk stratification biomarker among patients with/survivors of breast cancer.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Cancer survivorship; Cardio-oncology; Coronary artery calcium; Coronary microvascular disease; Myocardial flow reserve; Positron emission tomography

Year:  2021        PMID: 34820770      PMCID: PMC9126993          DOI: 10.1007/s12350-021-02825-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  40 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Waren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Int J Cardiovasc Imaging       Date:  2002-02       Impact factor: 2.357

2.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

3.  Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization.

Authors:  Viviany R Taqueti; Rory Hachamovitch; Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli
Journal:  Circulation       Date:  2014-11-16       Impact factor: 29.690

4.  Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.

Authors:  Laxmi S Mehta; Karol E Watson; Ana Barac; Theresa M Beckie; Vera Bittner; Salvador Cruz-Flores; Susan Dent; Lavanya Kondapalli; Bonnie Ky; Tochukwu Okwuosa; Ileana L Piña; Annabelle Santos Volgman
Journal:  Circulation       Date:  2018-02-01       Impact factor: 29.690

5.  Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease.

Authors:  A P Morise; W J Haddad; D Beckner
Journal:  Am J Med       Date:  1997-04       Impact factor: 4.965

Review 6.  Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis.

Authors:  Partha Sardar; Amartya Kundu; Saurav Chatterjee; Anju Nohria; Ramez Nairooz; Sripal Bangalore; Debabrata Mukherjee; Wilbert S Aronow; Carl J Lavie
Journal:  Clin Cardiol       Date:  2016-11-02       Impact factor: 2.882

7.  Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Robert T Dess; Yilun Sun; Martha M Matuszak; Grace Sun; Payal D Soni; Latifa Bazzi; Venkatesh L Murthy; Jason W D Hearn; Feng-Ming Kong; Gregory P Kalemkerian; James A Hayman; Randall K Ten Haken; Theodore S Lawrence; Matthew J Schipper; Shruti Jolly
Journal:  J Clin Oncol       Date:  2017-03-16       Impact factor: 44.544

8.  Coronary Microvascular Dysfunction Identifies Patients at High Risk of Adverse Events Across Cardiometabolic Diseases.

Authors:  Michael T Osborne; Navkaranbir S Bajaj; Viviany R Taqueti; Ankur Gupta; Paco E Bravo; Jon Hainer; Courtney F Bibbo; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli
Journal:  J Am Coll Cardiol       Date:  2017-12-05       Impact factor: 24.094

9.  Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.

Authors:  Jennifer L Patnaik; Tim Byers; Carolyn DiGuiseppi; Dana Dabelea; Thomas D Denberg
Journal:  Breast Cancer Res       Date:  2011-06-20       Impact factor: 6.466

10.  A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.

Authors:  C Noel Bairey Merz; Eileen M Handberg; Chrisandra L Shufelt; Puja K Mehta; Margo B Minissian; Janet Wei; Louise E J Thomson; Daniel S Berman; Leslee J Shaw; John W Petersen; Garrett H Brown; R David Anderson; Jonathan J Shuster; Galen Cook-Wiens; André Rogatko; Carl J Pepine
Journal:  Eur Heart J       Date:  2015-11-27       Impact factor: 35.855

View more
  1 in total

1.  Call on the reserve: Coronary vasomotor dysfunction is a potential biomarker of cardiovascular risk in patients with breast cancer.

Authors:  Michael T Osborne; Simran Grewal; Tomas G Neilan
Journal:  J Nucl Cardiol       Date:  2021-12-14       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.